OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2020, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 3.3 weeks (median values) after submission.
Treatment of Dementia
Submission Deadline: November 30, 2019 (Open) Submit Now
Michael Fossel, MD, PhD
1. President of Telocyte (http://www.telocyte.com), Grand Rapids, MI 49503, USA
2. Retired Clinical Professor of Medicine, Michigan State University, Ada, MI 49301, USA
Research Interests: human aging; telomeres; telomerase therapy; age-related diseases; Alzheimer's disease
About This Topic
According to the recent report by the World Health Organization (WHO), as for the global dementia prevalence, the number of people with dementia in the world is now approximately 35.6 million. It is forecasted to increase to 39 million by 2050. Dementia is increasing worldwide, but more than half (58%) of the patients are concentrated in low- and middle-income countries, and this percentage will rise to more than 70% by 2050. The total cost of treating dementia and social loss worldwide is over 50 trillion yen (US $604 billion) per year. In this special feature, we will introduce efforts all over the world, and would like to outline the latest treatment of dementia in the world, in addition to pharmaceutical approaches, control over insulin resistance, diets, exercise, communication with others, mindfulness and other psychological approaches.
Title: Palliative Care in Dementia- when is the appropriate time to intiate?
Authors: SC Lim and Edward Poon
Title: Forgotten: Narratives of Age-Related Dementia and Alzheimer’s Disease in Canada by Marlene Goldman, Book Review
Author: Julia Henderson, PhD
Title: Usefulness of the Long-Term Intermittent Hypoxic - Hyperoxic Training (IHHT) in Alzheimer’s type Dementia Treatment: Two Case Studies
Author: Arkadi F. Prokopov
Title: Parting with the concept of Alzheimer´s disease in senium.
Authors: Kalvach P., Vogner M.
Title: Multimodal Treatment for Dementia: Collaborative Research with the NHS, Functional Medicine and Lifestyle Change
Authors: Dr. Garuth Chalfont, Dr. Jane Simpson, Dr. Sarah Davies, Dr. Leigh Willoughby, Dr. David Morris, Professor Christine Milligan
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.